Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 22, 2005. The report details a specific corporate action regarding the repurchase of the company's own shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 650,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,375.85 pence per share.
- Treasury Holdings: 116,588,000 shares held in Treasury following the transaction.
- Shares in Issue: 5,829,555,775 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback authorized by shareholders at the Annual General Meeting on May 25, 2005. The company executed this purchase on September 22, 2005, and intends to hold the acquired shares in Treasury.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Investor Verification Checklist
- Verify the total cost of the 650,000 share repurchase based on the disclosed price of 1,375.85 pence.
- Confirm the updated total share count (5,829,555,775 in issue) against subsequent filings.
- Review the Annual General Meeting minutes from May 25, 2005, to understand the full scope of the share buyback authorization.